MRK · Healthcare
What a holder would want to know before buying MRK: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.
Today’s price is 77% above the lowest point of the past year and 7% below the highest.
Over the past year it was cheaper than today on 90% of days and more expensive on 10%. Over the last 10 years: cheaper on 99% of days.
18% above its average price of the last 200 trading days.
Fell 20% or more 3 times in 10 years. The deepest fall was 45%; the longest took 2.1 years to get back to its peak. Every one recovered.
Now 7% below the Aug 2026 peak.
Merck & Co., Inc. · Healthcare · Drug Manufacturers - General · a mega-cap worth $359.22B
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance,…
revenue profit
Sales of $65.01B in 2025, with $18.25B of profit. Sales grew in 3 of the last 3 years.
Keeps about 5 cents of every dollar of sales as profit.
Would need about 3.6 years of free cash flow to repay all its debt.
You pay $116 for every $1 of last year’s profit, and $16 for every $1 of profit expected next year.
A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.
Pays 2.39% a year in dividends at today’s price · next ex-dividend Sep 15.
27 analysts: 19 say buy, 8 hold, 0 sell. Their average 12-month target is $158.28 (range $105.00–$186.00).
Insiders made 0 purchases and 7 sales in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.
Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.
Poshkan is paper trading: real prices, virtual money. Buy MRK with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.
Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.